Listar por autoría "2269bce5-1c7b-4350-b823-465e2bcc6bd6"

Mostrando ítems 1-4 de 4

    • openAccess   MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease 

      MILARA, JAVIER; Díaz-Platas, Lucía; Contreras, Sonia; Ribera, Pilar; Roger, Inés; Ballester, Beatriz; Montero, Paula; Cogolludo, Ángel; Morcillo, Esteban; Cortijo, Julio BMC (2018)
      Background Lung inflammation in COPD is poorly controlled by inhaled corticosteroids (ICS). Strategies to improve ICS efficacy or the search of biomarkers who may select those patients candidates to receive ICS in COPD ...

    • openAccess   Paclitaxel Induces Epidermal Molecular Changes and Produces Subclinical Alterations in the Skin of Gynecological Cancer Patients 

      Montero, Paula; Pérez-Leal, Martín; Pérez-Fidalgo, J. Alejandro; Sanz, Celia; Estornut, Cristina; Roger, Inés; MILARA, JAVIER; Cervantes, Andrés; Cortijo, Julio MDPI (2022-03-01)
      Background: Paclitaxel is a microtubule-stabilizing chemotherapeutic agent. Despite its widespread use, it damages healthy tissues such as skin. The goal of this study was to prove that the real impact of paclitaxel-induced ...

    • openAccess   Paclitaxel-Induced Epidermal Alterations: An In Vitro Preclinical Assessment in Primary Keratinocytes and in a 3D Epidermis Model 

      Sanz, Celia; Montero, Paula; MILARA, JAVIER; Pérez-Leal, Martín; Estornut, Cristina; Roger, Inés; Pérez-Fidalgo, J. Alejandro; Cortijo, Julio MDPI (2022-01-22)
      Paclitaxel is a microtubule-stabilizing chemotherapeutic agent approved for the treatment of ovarian, non-small cell lung, head, neck, and breast cancers. Despite its beneficial effects on cancer and widespread use, ...

    • openAccess   The JAK2 pathway is activated in idiopathic pulmonary fibrosis 

      MILARA, JAVIER; Hernandez, Gracia; Ballester, Beatriz; Morell, Anselm; Roger, Inés; Montero, P.; Escrivá, Juan; Lloris, José M.; Molina Molina, Maria; Morcillo, Esteban; Cortijo, Julio BioMed Central (2018)
      Background: Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal fibrotic disorder, with no curative therapies. The signal transducer and activator of transcription 3 (STAT3) protein is activated ...